Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis.

Xiao-Yong HuangPeng-Fei ZhangChuan-Yuan WeiRui PengJia-Cheng LuChao GaoJia-Bing CaiXuan YangJia FanAi-Wu KeJian ZhouGuo-Ming Shi

Published in: Molecular cancer (2020)

circMET is an onco-circRNA that induces HCC development and immune tolerance via the Snail/DPP4/CXCL10 axis. Furthermore, sitagliptin may enhance the efficacy of anti-PD1 therapy in a subgroup of patients with HCC.

Keyphrases

epithelial mesenchymal transition
stem cells
randomized controlled trial
signaling pathway
open label
phase iii